640.F China Resources Pharmaceutical Group Limited
- Market cap
- EUR 3.17B
- P/E
- 6.3x
- P/B
- 0.46x
- ROE
- 7.9%
- Dividend yield
- 5.21%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 640.F undervalued?
Graham number640.F trades 64.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China Resources Pharmaceutical Group Limited fundamental analysis
No fundamental analysis for China Resources Pharmaceutical Group Limited yet.
China Resources Pharmaceutical Group Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China Resources Pharmaceutical Group Limited
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products…
Full company profileChina Resources Pharmaceutical Group Limited financial statements
China Resources Pharmaceutical Group Limited annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 157B | 173B | 190B | 204B | 200B | 237B | 254B | 245B | 258B | 270B |
| Gross Profit | 24.1B | 28.3B | 34.9B | 34.0B | 32.3B | 35.4B | 39.1B | 38.3B | 40.7B | 44.5B |
| Operating Income | 9.21B | 10.2B | 11.8B | 9.63B | 11.3B | 12.2B | 14.1B | 12.8B | 13.8B | 14.5B |
| EBITDA | - | 12.4B | 13.8B | 12.7B | 10.2B | 11.2B | 15.9B | 15.4B | 16.6B | 17.9B |
| Net Income | 2.82B | 3.48B | 4.04B | 3.29B | 3.30B | 3.77B | 4.15B | 3.85B | 3.35B | 4.05B |
| EPS | - | 0.55 | 0.64 | 0.52 | 0.52 | 0.60 | 0.66 | 0.61 | 0.53 | 0.64 |
| Balance Sheet | ||||||||||
| Total Assets | 134B | 161B | 176B | 190B | 209B | 249B | 241B | 247B | 258B | 286B |
| Total Liabilities | 79.7B | 97.6B | 116B | 120B | 129B | 154B | 151B | 154B | 160B | 168B |
| Shareholders' Equity | 37.6B | 41.9B | 39.4B | 40.7B | 46.5B | 51.0B | 49.6B | 46.0B | 48.2B | 51.4B |
| Cash & Short-term Investments | 14.0B | 14.2B | 16.6B | 12.5B | 11.2B | 17.5B | 17.0B | 24.7B | 16.4B | 15.8B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 4.12B | 4.86B | 8.25B | 8.14B | 8.21B | 12.8B | 12.6B | 15.5B | 17.5B | 20.5B |
| Capital Expenditure | 1.83B | 1.57B | 1.52B | 1.65B | 1.67B | 2.41B | 3.49B | 3.13B | 3.20B | 3.55B |
| Free Cash Flow | - | 2.85B | 6.27B | 6.10B | 5.99B | 9.70B | 9.15B | 12.4B | 14.3B | 16.9B |
| Ratios | ||||||||||
| ROE | 7.5% | 8.3% | 10.3% | 8.1% | 7.1% | 7.4% | 8.4% | 8.4% | 6.9% | 7.9% |
| ROA | 2.1% | 2.2% | 2.3% | 1.7% | 1.6% | 1.5% | 1.7% | 1.6% | 1.3% | 1.4% |
| Net Profit Margin | 1.8% | 2.0% | 2.1% | 1.6% | 1.6% | 1.6% | 1.6% | 1.6% | 1.3% | 1.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
China Resources Pharmaceutical Group Limited dividends
- Dividend yield
- 5.21%
- Forward dividend
- 0.03 EUR
- Payout ratio
- 19.3%
- Ex-dividend date
- Sep 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 779M | 0.12 | 19.3% |
| 2024 | CNY 1.49B | 0.24 | 44.4% |
| 2023 | CNY 880M | 0.14 | 22.8% |
| 2022 | CNY 942M | 0.15 | 22.7% |
| 2021 | CNY 754M | 0.12 | 20.0% |
| 2020 | CNY 691M | 0.11 | 21.0% |
| 2019 | EUR 817M | 0.13 | 24.9% |
| 2018 | EUR 691M | 0.11 | 17.1% |
| 2017 | EUR 566M | 0.09 | 16.2% |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns China Resources Pharmaceutical Group Limited
- Insiders 70.83%
- Institutions 5.91%
- Public & others 23.27%
- Shares outstanding 6.28B
- Free float 1.83B
China Resources Pharmaceutical Group Limited company profile
- Company name
- China Resources Pharmaceutical Group Limited
- Ticker
- 640.F
- ISIN
- HK0000311099
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 84,000
- Fiscal year end
- December
- Address
- China Resources Building, Wan Chai, Hong Kong
- Phone
- 852 2593 8991
- Website
- crpharm.com
About China Resources Pharmaceutical Group Limited
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular, metabolism, intravenous infusion, and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operating retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, Kun Zhong Yao, and Tasly to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited operates as a subsidiary of CRH (Pharmaceutical) Limited.
China Resources Pharmaceutical Group Limited management
10- Mr. Xiaosong BaiExecutive Chairman of the Board · born 1971
- Mr. Jie ChengPresident & Executive Director · born 1979
- Madam Rong DengChief Financial Officer · born 1978
- Mr. Changan LiuExecutive Director · born 1974
- Yanwei HuangCFO of CR Jiangzhong
- Guo JunyuVP and Chief Strategy Officer of CR Business Group
- Ren HuiPresident of Boya Bio-pharmaceutical
- Ju LiuBoard Secretary & VP of China Res Double-Crane
- Ms. Wing Yi WanCompany Secretary
- Mr. Ting GuoChairman of China Resources Pharmaceutical Commercial Group